1-5 of 5
Anh Tran
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tet2 Inactivation Enhances the Anti-Tumor Activity of Tumor-Infiltrating Lymphocytes (TILs) to Curtail Melanoma Growth

Minjung Lee, PhD, Jianfang Li, PhD, Shaohai Fang, MS, Joanna Zhang, Anh Tran Tram Vo, Wei Han, MS, Hongxiang Zeng, PhD, Sevinj Isgandarova, Margarita Martinez Moczygemba, PhD, Yubin Zhou, PhD, Jia Li, PhD, Deqiang Sun, PhD, Yun Huang, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27.
https://doi.org/10.1182/blood-2020-137242
Published: 2020
Journal Articles

A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Andre Goy, MD, Radhakrishnan Ramchandren, MD, Nilanjan Ghosh, MD PhD, Javier Munoz, MD, David S. Morgan, MD, Nam H. Dang, MD PhD, Mark Knapp, MD, Maria Delioukina, MD, Edwin C. Kingsley, MD, Anh Tran, BS, Jerry Ping, PhD, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, Jia Ruan, MD PhD
Journal: Blood
Blood (2016) 128 (22): 473.
https://doi.org/10.1182/blood.V128.22.473.473
Published: 2016
Journal Articles

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Jennifer R. Brown, Jacqueline C. Barrientos, Paul M. Barr, Ian W. Flinn, Jan A. Burger, Anh Tran, Fong Clow, Danelle F. James, Thorsten Graef, Jonathan W. Friedberg, Kanti Rai, Susan O’Brien
Journal: Blood
Blood (2015) 125 (19): 2915–2922.
https://doi.org/10.1182/blood-2014-09-585869
Published: 2015
Includes: Supplemental data
Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD, PhD, Jan A. Burger, MD, PhD, Kristie A. Blum, MD, Jeff Sharman, MD, Barbara Grant, MD, Jeffrey A. Jones, MD, MPH, William G. Wierda, MD, Ph.D., Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Anh Tran, Fong Clow, ScD, Lori Kunkel, MD, Danelle F. James, M.D, Susan O'Brien, MD
Journal: Blood
Blood (2012) 120 (21): 189.
https://doi.org/10.1182/blood.V120.21.189.189
Published: 2012
Journal Articles

Differential effect of agonistic anti-CD40 on human mature and immature dendritic cells: the Janus face of anti-CD40

Marie-Ghislaine de Goër de Herve, Deniz Durali, Tú-Anh Tran, Gwénola Maigné, Federico Simonetta, Philippe Leclerc, Jean-François Delfraissy, Yassine Taoufik
Journal: Blood
Blood (2005) 106 (8): 2806–2814.
https://doi.org/10.1182/blood-2004-12-4678
Published: 2005